Chemoimmunotherapy in Non-Hodgkin's Lymphoma CHOP-Bleomycin vs. CHOP + BCG vs. COP + Bleomycin Induction Therapy; No Maintenance vs. BCG for Maintenance

Non-hodgkins lymphoma

R Fisher;P Mauch;J Friedberg;L Rimsza In Cancer: Principles and Practice of Oncology, 8th edition, Lippincott, Williams & Wilkins, Baltimore, MD, pp 2098-2158, 2008

New treatment options have changed the survival of patients with follicular lymphoma

RI Fisher;M LeBlanc;OW Press;DG Maloney;JM Unger;TP Miller Journal of Clinical Oncology 23(33):8447-8452

New REAL clinical entities.

RI Fisher;TP Miller;TM Grogan Cancer Journal from Scientific American 4(Suppl.2):S5-S12

Follicular lymphomas: Do histologic subtypes predict outcome?

TP Miller;M LeBlanc;TM Grogan;RI Fisher Hematology/Oncology Clinics of North America 11(5):893-900

Evaluation and management of mantle cell lymphoma.

OW Press;TM Grogan;RI Fisher Advances in Leukemia and Lymphoma 6(1):3-11

Clinical course and therapy of mantle cell lymphoma.

RI Fisher;OW Press;TP Miller;DR Head Principles and Practice of Oncology 10(6):1-7

Mantle-cell lymphoma: Classification and therapeutic implications.

RI Fisher Annals of Oncology 7(Suppl.6):S35-S39

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

BW Dana;S Dahlberg;BN Nathwani;E Chase;C Coltman;TP Miller;RI Fisher Classic Papers and Current Comments 1(2):320-328

A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid b-cell subcategories: A Southwest Oncology Group study.

RI Fisher;S Dahlberg;BN Nathwani;PM Banks;TP Miller;TM Grogan Blood 85(4):1075-1082

A clinical analysis of new indolent lymphoma entities in the revised european american lymphoma (REAL) classification.

RI Fisher;S Dahlberg;TM Grogan ASCO 13:379(#1287)

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

BW Dana;S Dahlberg;BN Nathwani;E Chase;CA Coltman Jr;TP Miller;RI Fisher JCO 11(4):644-651

Treatment of diffuse large-cell lymphoma: A summary of outcome for patients treated by the Southwest Oncology Group.

TP Miller;S Dahlberg Malignant Lymphomas Including Hodgkins Disease 4:53-63

Long-term followup of patients with low grade lymphoma treated with CHOP ( cyclophosphamide, doxorubicin, vincristine, prednisone)-based chemotherapy or chemoimmunotherapy on Southwest Oncology Group studies

B Dana;S Dahlberg;T Miller;S Jones;E Chase;C Coltman, Jr;R Fisher ASCO 8:257(#1001)

Long-term survival of patients with nodular histiocytic (NH),diffuse poorly differentiated lymphocytic (DPDL), diffuse mixed (DM),and diffuse undifferentiated (DU) lymphoma treated with CHOP chemotherapy.

RI Fisher;S Dahlberg;TP Miller;SE Jones;C Coltman, Jr ASCO 8:257(#1003)

Mitotic counts in follicular lymphomas.

DJ Ellison;BN Nathwani;GE Metter;RR Turner;JS Burke;TP Miller;RB Mann;M Barcos;CR Kjeldsberg;CD Winberg;CC Whitcomb Human Pathology 18:502-505

Effect of age on therapeutic outcome in advanced diffusehistiocytic lymphoma: the Southwest Oncology Group experience.

DO Dixon;BA Neilan;SE Jones;DA Lipschitz;TP Miller;SE Salmon;PN Grozea;SP Balcerzak JCO 4(3):296-305

What should be the morphologic criteria for the subdivision offollicular lymphomas?

BN Nathwani;GE Metter;TP Miller;JS Burke;RB Mann;M Barcos;CR Kjeldsberg;DO Dixon;CD Winberg;CC Whitcomb;SE Jones Blood 68(4):837-845

CHOP is curative in thirty percent of patients with diffuse largecell lymphoma: A twelve year Southwest Oncology Group followup.

C Coltman, Jr;S Dahlberg;SE Jones;TP Miller;BW Dana;EM McKelvey;RJ Hartsock;DO Dixon ASCO 5:197(#774)

Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for lymphoma clinical studies.

GE Metter;BN Nathwani;JS Burke;CD Winberg;RB Mann;M Barcos;CR Kjeldsberg;CC Whitcomb;DO Dixon;TP Miller;SE Jones JCO 3(1):25-38

Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group study

SE Jones;PN Grozea;EN Metz;A Haut;RL Stephens;FS Morrison;R Talley;JJ Butler;GE Byrne;R Hartsock;D Dixon;SE Salmon Cancer 51:1083-1090

The clinical significance of the morphologic subdivision of diffuse, "Histiocytic" Lymphoma: A study of 162 patients treated by the Southwest Oncology Group

BN Nathwani;DO Dixon;SE Jones;RT Hartsock;JW Rebuck;GE Byrne Jr;WW Sheehan;H Kim;CA Coltman Jr;H Rappaport Blood 60:1068-1074

Chemoimmunotherapy of malignant lymphoma

SE Jones In: Of Human Cancer, W Terry, S Rosenberg, eds. New York: Elsevier-North Holland 55-60

Lymphoblastic lymphoma: A clinicopathologic study of 95 patients

BN Nathwani;LW Diamond;CD Winberg;H Kim;RM Bearman;JH Glick;SE Jones;RA Gams;NI Nissen;H Rappaport Cancer 48:2347-2357

The chemotherapy of lymphoblastic lymphoma

JB Voakes;SE Jones;EM McKelvey Blood 57:186-188

Chemoimmunotherapy of Non-Hodgkin's lymphoma

SE Jones;SE Salmon;C Haskins Immunotherapy of Cancer: Present Status of Trials in Man, p. 28 April

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. A Southwest Oncology Group study

SE Jones;PN Grozea;EN Metz;A Haut;RL Stephens;FS Morrison;JS Butler;GE Byrne Jr;TE Moon;R Fisher;CL Haskins;CA Coltman Jr Cancer 43(2):417-425

Involvement of the central nervous system by non- Hodgkin's lymphoma. The Southwest Oncology Group experience

T Herman;N Hammond;S Jones;J Butler;G Byrne;E McKelvey Cancer 43(1): 390-397

Adjuvant immunotherapy with BCG in non-Hodgkin's lymphoma

S Jones;S Salmon;R Fisher In: Adjuvant Therapy of Cancer II , pp.163-171

Improved survival in nodular lymphomas with chemoimmunotherapy

S Jones;S Salmon;R Fisher;C Haskins;G Byrne;J Butler ASCO #C-89

Improved survival in nodular lymphomas with chemoimmunotherapy

S Jones;S Salmon;R Fisher;C Haskins;G Byrne;J Butler Proc AACR 20:313

Adjuvant use of BCG in the non-Hodgkin's lymphomas

S Jones;S Salmon International Conference on the Adjuvant Therapy of Cancer #17

Systematic restaging in non-Hodgkin's lymphoma: the need to define complete remission

TS Herman;SE Jones Recent Results in Cancer Res 65:73-80

Systematic restaging in patients with Hodgkin's disease: a Southwest Oncology Group study

TS Herman;SE Jones Cancer 42(4):1976-1978

Systematic re-staging in the management of non- Hodgkin's lymphomas

TS Herman;SE Jones Cancer Treat Rep 61:1009-1015

Adjuvant immunotherapy with BCG in lymphoma

SE Jones;SE Salmon In: Adjuvant Therapy of Cancer Salmon SE, Jones SE (eds), Elsevier/ North Holland Press, Amsterdam, pp.549-556

Chemoimmunotherapy of non-Hodgkin's lymphoma with BCG: A preliminary report

SE Jones;SE Salmon;TE Moon;JJ Butler In: Immunotherapy of Cancer: Present Status of Trials in Man Terry, WD, Windhorst, D. (eds), Raven Press, New York, pp.519-528

Systematic restaging in Hodgkin's disease

TS Herman;SE Jones AACR #386

Chemoimmunotherapy of non-Hodgkin's lymphoma (NHL)

SE Jones;SE Salmon;TE Moon;JJ Butler ASCO #C-100

Lymphoma pathology repository review in the Southwest Oncology Group (SWOG)

SE Jones;JJ Butler;GE Byrne Jr;CA Coltman Jr ASCO 17:249 (#C-49)